Company Profile - JSP PHARMACEUTICAL MANUFACTURING (THAILAND) PUBLIC COMPANY LIMITED สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 09 August 2024 20:12 Company Profile JSP

addition, the economic impact of Covid-19 will be only fully visible in the Q2-Q4 period of the year. However, as our business is essential to many manufacturing processes, and as we are quite diversified

the first time. The economics of scale has already improved and the synergetic effect between both companies will increase throughout 2019 particularly on the fixed cost side. EBITDA in Q1 2018 improved

expectations. On the cost side a major external factor was the change in Thai legislative environment, which made it necessary to build major additional retirement provision in Q2. On top of the external factors

improve from spending in all categories, consistent with the expansion of manufacturing production in both domestic and export-related industries. Exports in the first three months have jumped 11.3% year on

sectors. Tourism was heavily affected by airspace and border closures, while merchandise exports fell sharply as demand from major trading partners fell, impacting both manufacturing production and domestic

commercial and passenger cars. Export-related manufacturing production, especially automotive, has continued to improve. The consensus view for 4% GDP growth in 2018 maybe revised upwards given the strong end

slower pace than 2018 at around 7-8 % supported by fixed asset investment. Certain other key segments like chemical and construction (AAC block manufacturing) also show positive tendencies. On the downside

ที่ กบร No. Kor Bor Ror. 032/2017 November 9, 2017 President The Stock Exchange of Thailand Re : Increase of the investment proportion in the ordinary shares of Pattaya Manufacturing Co., Ltd. Dear

1 No. LorBor. 11/2019 May 13, 2019 Re: Joint Venture in Pulp Mold Manufacturing Project Attn.: President The Stock Exchange of Thailand Kaset Thai International Sugar Corporation Public Company